Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer — The View From Goodwin <em>(Chambers Associate)</em>

main

07_12 Becoming a Life Sciences Lawyer

Seven partners from Goodwin share their views on what it takes to become a successful life sciences lawyer. 

Becoming a Life Sciences Lawyer — The View From Goodwin (Chambers Associate)

Related Content

A Recap of Resilience: Goodwin’s Life Sciences Practice

Congress Passes Legislation Codifying FDA’s “Active Moiety” Approach to Exclusivity Determinations

Changes To March-In Rights Under Bayh-Dole And More?

Moving from the Informed Consent to Approved Labeling: Preparing for Risks in Product Marketing & Use

Congress Enacts Amendments Affecting The Regulation Of Generic Drugs And Biosimilars

Webinar Recording: Challenges from the East, Asia Biopharma, and Responses to COVID

Strategic Considerations for Seeking Patent Term Extension (PTE) and its Scope for Drug Products

Webinar Recording: Modifying Clinical Trials: Regulatory, Liability & Insurance Considerations

Life Sciences Pennsylvania & Goodwin’s Rachael Bushey (Being a Life Sciences Leader)

Patent Licensing (The Licensing Journal)

Gregory E. Demske, Former Chief Counsel to the HHS Inspector General and Leading Healthcare Fraud and Abuse Attorney, Joins Goodwin in Washington D.C.

With New Pricing Law, the Feds Can Make Drug Firms Offers They Really Can't Refuse (RealClearInvestigations)

U.S. Legislative Update: Takeaways for European Pharma (European Pharmaceutical Review)

U.S. Courts Annual Review - First Circuit (Global Competition Review)

Kirk Ogrosky, Top Trial Lawyer and Former DOJ Healthcare Fraud Enforcement Trailblazer, Joins Goodwin in Washington, D.C.

Chambers Global 2022 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

Pharmaceuticals

Life Sciences

FDA Litigation